Research prototype, not medical advice.

In a phase 1 trial (5 people with mild Alzheimer), dasatinib reached the cerebrospinal fluid but quercetin did not; tolerance was acceptable.

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Cellular senescenceDasatinib + quercetin (D+Q)Alzheimer's disease

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
Gonzales et al. · Nature Medicine 2023
— Verified